- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07525141
Een studie van JNJ-1761981 bij deelnemers met solide tumoren
Fase 1-studie van intratumorale toediening van JNJ-1761981 ER, een chemotherapie met verlengde afgifte, bij deelnemers met solide tumoren
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Study Contact
- Telefoonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studie Locaties
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224
- Werving
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic Rochester
-
-
New York
-
The Bronx, New York, Verenigde Staten, 10467
- Werving
- Montefiore Medical Center
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- MD Anderson Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
- Part 1: Individuals with a diagnosis of locally advanced or metastatic disease (solid tumors except tumors of the central nervous system [CNS]) who have previously received available standard therapy and progressed, or cannot tolerate standard therapy, or for whom there is no standard of care per regional guidelines
- Part 2 Cohort A: Individuals with histologically or cytologically confirmed metastatic tumors of adenocarcinoma or squamous cell carcinoma histology, for which any platinum-based systemic regimen is considered a standard of care (per national comprehensive cancer network [NCCN] guidelines) and whose disease has progressed after standard therapy
- Eastern cooperative oncology group performance status (ECOG) performance status of Grade 0 or 1
- Part 2 Cohort A participants planned to receive optional cetrelimab (participants not meeting this criterion may still be enrolled in the study but cannot receive cetrelimab): Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy
- A participant of childbearing potential must practice at least 2 highly effective methods of contraception throughout the study and through 14 months (for women) and 11 months (for men) after the last dose of JNJ-1761981 or 5 months after the last dose of cetrelimab or other anti-PD(L)1 treatment, whichever is later
Exclusion criteria:
- Active symptomatic disease involvement of the central nervous system
- Prior or concurrent second malignancy (other than the disease under study) that due to natural history or treatment is likely to interfere with any study endpoints of safety or the antitumor activity of the study treatment(s)
- Active bleeding diathesis or requirement for therapeutic anticoagulation that cannot be interrupted or altered for procedures
- Known allergies, hypersensitivity, or intolerance to JNJ-1761981 or its excipients
- Lesions invading or adjacent to major blood vessels or other critical structures (for example, airways) not suitable for injection
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1: Dose Escalation
Participants will receive JNJ-1761981 intratumorally to determine a safe and tolerable total JNJ-1761981 dose. |
JNJ-1761981 will be administered intratumorally. |
|
Experimenteel: Part 2: Dose Expansion
Participants in Cohort A will receive JNJ-1761981 at specified volumetric doses. Participants who receive more than 1 dose of JNJ-1761981 may receive optional systemic therapy with cetrelimab at the discretion of the treating physician. |
JNJ-1761981 will be administered intratumorally. Cetrelimab will be administered intravenously.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1: Number of Participants with Adverse Events (AE) by Severity
Tijdsspanne: Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 2 years 10 months
|
|
Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)
Tijdsspanne: Up to 28 days
|
High grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation will be regarded as DLT. |
Up to 28 days
|
|
Part 1: Number of Participants with AEs by Severity Related to Delivery Device and/or Procedure
Tijdsspanne: Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Participants with AEs related to delivery device and/or procedure will be reported. |
Up to approximately 2 years 10 months
|
|
Part 1: Number of Participants who Received Planned Total Dose per Level
Tijdsspanne: Up to approximately 28 days
|
Number of participants who received planned total dose per level will be reported. |
Up to approximately 28 days
|
|
Part 2: Administered Tumor Response Rate
Tijdsspanne: Up to approximately 2 years 10 months
|
Administered tumor response rate is defined as the percentage of JNJ-1761981 administered lesions that achieve complete response (CR) or partial response (PR). |
Up to approximately 2 years 10 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Parts 1 and 2: Plasma Concentration of Free and Total Platinum
Tijdsspanne: Up to approximately 2 years 10 months
|
Plasma concentration of free and total platinum will be assessed. |
Up to approximately 2 years 10 months
|
|
Part 1: Administered Tumor Response Rate
Tijdsspanne: Up to approximately 2 years 10 months
|
Administered tumor response rate is defined as the percentage of JNJ-1761981 administered lesions that achieve CR or PR. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Administered Tumor Duration of Response
Tijdsspanne: Up to approximately 2 years 10 months
|
Administered tumor duration of response will be calculated among JNJ-1761981 administered lesions that responded from the date of initial documentation of lesion response to the date of first documented evidence of progression or start of subsequent anticancer treatment or death due to any cause, whichever occurs first. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 2 years 10 months
|
ORR is defined as the percentage of participants who have best response of Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Disease Control Rate (DCR)
Tijdsspanne: Up to approximately 2 years 10 months
|
DCR is defined as the percentage of participants who have achieved CR, PR, and stable disease for at least 4 weeks after study treatment was administered. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Duration of Response (DOR)
Tijdsspanne: Up to approximately 2 years 10 months
|
DOR will be calculated among responders from the date of initial documentation of a response (first CR/PR) to the date of first documented evidence of progression according to RECIST v.1.1, or death due to any cause, whichever occurs first. |
Up to approximately 2 years 10 months
|
|
Part 2: Number of Participants with Adverse Events (AE) by Severity
Tijdsspanne: Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the NCI-CTCAE v 5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 2 years 10 months
|
|
Part 2: Number of Participants with AE by Severity Related to Delivery Device and/or Procedure
Tijdsspanne: Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Participants with AEs related to delivery device and/or procedure will be reported. |
Up to approximately 2 years 10 months
|
|
Part 2: Number of Participants who Received Planned Intratumoral Volumetric Dose
Tijdsspanne: Up to approximately 2 years 10 months
|
Number of participants who received the planned intratumoral volumetric dose will be reported. |
Up to approximately 2 years 10 months
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Johnson & Johnson Enterprise Innovation, Inc Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1761981STM1001
- 1761981STM1001 (Andere identificatie: Janssen Research & Development, LLC)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .